Entera Bio (ENTX) Other Non-Current Liabilities (2025)
Entera Bio (ENTX) recorded quarterly Other Non-Current Liabilities of $393000.0 in Q4 2025.
Entera Bio (ENTX) Other Non-Current Liabilities (2025) Analysis & Trends
Entera Bio has disclosed Other Non-Current Liabilities across 1 years of filings, most recently posting $393000.0 for Q4 2025.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $393000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $393000.0 (changed N/A YoY) and the FY2025 annual result came in at $393000.0, changed N/A from the prior year.
- Other Non-Current Liabilities held at $393000.0 in Q4 2025.
- Over five years, Other Non-Current Liabilities peaked at $393000.0 in Q4 2025 and troughed at $393000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 393,000.00 |